Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 8, 2014, Pages

  Williet, Nicolas ^a   Sandborn, William J ^b   Peyrin Biroulet, Laurent ^a  

^a INSERM   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's Disease; Health related quality of life; Ulcerative colitis

Indexed keywords

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL (TOPIC); DEPRESSION; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATORY BOWEL DISEASE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; DRUG MONITORING; INFLAMMATORY BOWEL DISEASES; PATIENT SATISFACTION; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; ANXIETY; CROHN DISEASE ACTIVITY INDEX; HOSPITAL ANXIETY AND DEPRESSION SCALE; MAINTENANCE THERAPY; PATHOPHYSIOLOGY; PATIENT REPORTED OUTCOME; RHEUMATOID ARTHRITIS; WORK DISABILITY;

DRUG MONITORING; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT SATISFACTION; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB;

EID: 84904393612     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.02.016     Document Type: Article

References (143)

1. Corsetti M., Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?. Neurogastroenterol Motil 2013, 25:453-457.
2. Spiegel B., Bolus R., Harris L.A., et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther 2009, 30:1159-1170.
3. Guyatt G., Mitchell A., Irvine E.J., et al. Anew measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
4. Love J.R., Irvine E.J., Fedorak R.N. Quality of life in inflammatory bowel disease. JClin Gastroenterol 1992, 14:15-19.
5. Irvine E.J., Zhou Q., Thompson A.K. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996, 91:1571-1578.
6. Yellen S.B., Cella D.F., Webster K., et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. JPain Symptom Manage 1997, 13:63-74.
7. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4:353-365.
8. Reilly M.C., Gerlier L., Brabant Y., et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008, 30:393-404.
9. Zung W.W. The Depression Status Inventory: an adjunct to the self-rating depression scale. JClin Psychol 1972, 28:539-543.
10. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
11. Beck A.T., Ward C.H., Mendelson M., et al. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
12. Peyrin-Biroulet L., Cieza A., Sandborn W.J., et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012, 61:241-247.
13. Drossman D.A., Leserman J., Li Z.M., et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991, 53:701-712.
14. Ware J.E., Sherbourne C.D. The MOS 36-item Short-form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
15. Jenkinson C., Gray A., Doll H., et al. Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care 1997, 35:1109-1118.
16. Kiran R.P., Delaney C.P., Senagore A.J., et al. Prospective assessment of Cleveland Global Quality of Life (CGQL) as a novel marker of quality of life and disease activity in Crohn's disease. Am J Gastroenterol 2003, 98:1783-1789.
17. Grunberg S.M., Groshen S., Steingass S., et al. Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 1996, 5:65-72.
18. Otley A., Smith C., Nicholas D., et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. JPediatr Gastroenterol Nutr 2002, 35:557-563.
19. Varni J.W., Seid M., Rode C.A. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999, 37:126-139.
20. Smets E.M., Garssen B., Bonke B., et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. JPsychosom Res 1995, 39:315-325.
21. Piper B.F. Piper fatigue scale available for clinical testing. Oncol Nurs Forum 1990, 17:661-662.
22. Fisk J.D., Ritvo P.G., Ross L., et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994, 18(Suppl 1):S79-S83.
23. Spielberger C.D., Gorsuch R.I., Lushene R.E., et al. STAI manual for the State-Trait Anxiety Inventory 1970, Consulting Psychologist Press, Palo Alto, CA.
24. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006, 4:79.
25. Klenner F.R. Fatigue, normal and pathological, with special consideration of myasthenia gravis and multiple sclerosis. South Med Surg 1949, 111:273-277.
26. Mac L.A., Berkson J. Mortality and disability in multiple sclerosis; a statistical estimate of prognosis. JAMA 1951, 146:1367-1369.
27. Villiaumey J. [Medicosocial consequences of inflammatory rheumatism]. Soins 1978, 23:47-51.
28. Wolfe F., Hawley D.J., Wilson K. The prevalence and meaning of fatigue in rheumatic disease. JRheumatol 1996, 23:1407-1417.
29. Bansback N., Zhang W., Walsh D., et al. Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA. Rheumatology (Oxford) 2012, 51:375-384.
30. Kalyoncu U., Dougados M., Daures J.P., et al. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009, 68:183-190.
31. Fries J.F., Spitz P., Kraines R.G., et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145.
32. Pavelka K., Szekanecz Z., Damjanov N., et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clin Rheumatol 2013, 2013:11.
33. Strand V., Rentz A.M., Cifaldi M.A., et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. JRheumatol 2012, 39:63-72.
34. Rigby W., Ferraccioli G., Greenwald M., et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken) 2011, 63:711-720.
35. Pincus T., Swearingen C., Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999, 42:2220-2230.
36. Chauffier K., Salliot C., Berenbaum F., et al. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford) 2012, 51:60-68.
37. Dougados M., Nataf H., Steinberg G., et al. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology (Oxford) 2013, 52:391-399.
38. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
39. Cohen J.A., Reingold S.C., Polman C.H., et al. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012, 11:467-476.
40. Vickrey B.G., Hays R.D., Harooni R., et al. Ahealth-related quality of life measure for multiple sclerosis. Qual Life Res 1995, 4:187-206.
41. Cella D.F., Dineen K., Arnason B., et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996, 47:129-139.
42. Barnes D., Hughes R.A., Morris R.W., et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997, 349:902-906.
43. Stephenson J.J., Kern D.M., Agarwal S.S., et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. Health Qual Life Outcomes 2012, 10:155.
44. Deisseroth A., Kaminskas E., Grillo J., et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 2012, 18:3212-3217.
45. Verstovsek S., Mesa R.A., Gotlib J., et al. Adouble-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. NEngl J Med 2012, 366:799-807.
46. Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. NEngl J Med 2012, 366:787-798.
47. Mesa R.A., Gotlib J., Gupta V., et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. JClin Oncol 2013, 31:1285-1292.
48. Mesa R.A., Shields A., Hare T., et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res 2013, 37:911-916.
49. Harrison C.N., Mesa R.A., Kiladjian J.J., et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 2013, 162:229-239.
50. Bergman L., Krause U. Crohn's disease. A long-term study of the clinical course in 186 patients. Scand J Gastroenterol 1977, 12:937-944.
51. Meyers S., Walfish J.S., Sachar D.B., et al. Quality of life after surgery for Crohn's disease: a psychosocial survey. Gastroenterology 1980, 78:1-6.
52. Kock N.G., Darle N., Kewenter J., et al. The quality of life after proctocolectomy and ileostomy: a study of patients with conventional ileostomies converted to continent ileostomies. Dis Colon Rectum 1974, 17:287-292.
53. Blondel-Kucharski F., Chircop C., Marquis P., et al. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001, 96:2915-2920.
54. van der Have M., van der Aalst K.S., Kaptein A.A., et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. JCrohns Colitis 2014, 8:93-106.
55. Hoivik M.L., Moum B., Solberg I.C., et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis 2012, 18:1540-1549.
56. Pallis A.G., Mouzas I.A. Instruments for quality of life assessment in patients with inflammatory bowel disease. Dig Liver Dis 2000, 32:682-688.
57. Blank C., Switzer G.E. The use of questionnaires in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2006, 8:244-247.
58. McColl E., Han S.W., Barton J.R., et al. Acomparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004, 13:805-811.
59. Irvine E.J., Feagan B., Rochon J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-296.
60. Russel M.G., Pastoor C.J., Brandon S., et al. Validation of the Dutch translation of the Inflammatory Bowel Disease Questionnaire (IBDQ): a health-related quality of life questionnaire in inflammatory bowel disease. Digestion 1997, 58:282-288.
61. Cheung W.Y., Garratt A.M., Russell I.T., et al. The UK IBDQ-a British version of the inflammatory bowel disease questionnaire. Development and validation. JClin Epidemiol 2000, 53:297-306.
62. Hjortswang H., Jarnerot G., Curman B., et al. Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. Scand J Gastroenterol 2001, 36:77-85.
63. Pallis A.G., Vlachonikolis I.G., Mouzas I.A. Quality of life of Greek patients with inflammatory bowel disease. Validation of the Greek translation of the inflammatory bowel disease questionnaire. Digestion 2001, 63:240-246.
64. Bernklev T., Moum B., Moum T. Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ. Scand J Gastroenterol 2002, 37:1164-1174.
65. Hashimoto H., Green J., Iwao Y., et al. Reliability, validity, and responsiveness of the Japanese version of the Inflammatory Bowel Disease Questionnaire. JGastroenterol 2003, 38:1138-1143.
66. Pontes R.M., Miszputen S.J., Ferreira-Filho O.F., et al. [Quality of life in patients with inflammatory bowel diseases: translation to Portuguese language and validation of the "Inflammatory Bowel Disease Questionnaire" (IBDQ)]. Arq Gastroenterol 2004, 41:137-143.
67. Ren W.H., Lai M., Chen Y., et al. Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2007, 13:903-910.
68. Masachs M., Casellas F., Malagelada J.R. [Spanish translation, adaptation, and validation of the 32-item questionnaire on quality of life for inflammatory bowel disease(IBDQ-32)]. Rev Esp Enferm Dig 2007, 99:511-519.
69. Ciccocioppo R., Klersy C., Russo M.L., et al. Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire. Dig Liver Dis 2011, 43:535-541.
70. Lichtiger S., Binion D.G., Wolf D.C., et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010, 32:1228-1239.
71. Panaccione R., Loftus E.V., Binion D., et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011, 25:419-425.
72. Jelsness-Jorgensen L.P., Moum B., Bernklev T. Worries and concerns among inflammatory bowel disease patients followed prospectively over one year. Gastroenterol Res Pract 2011, 2011:492034.
73. Jelsness-Jorgensen L.P., Bernklev T., Henriksen M., et al. Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up. JCrohns Colitis 2012, 6:887-894.
74. Feagan B.G., Yan S., Bala M., et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003, 98:2232-2238.
75. Sands B.E., Blank M.A., Patel K., et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004, 2:912-920.
76. Loftus E.V., Feagan B.G., Colombel J.F., et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008, 103:3132-3141.
77. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009, 104:1170-1179.
78. Watanabe M., Hibi T., Lomax K.G., et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. JCrohns Colitis 2012, 6:160-173.
79. Strand V., Burmester G.R., Ogale S., et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 2012, 51:1860-1869.
80. Fernandez O., Baumstarck-Barrau K., Simeoni M.C., et al. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult Scler 2011, 17:1238-1249.
81. Feagan B.G., Coteur G., Tan S., et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009, 104:1976-1983.
82. Probert C.S., Hearing S.D., Schreiber S., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998-1002.
83. Lichtenstein G.R., Bala M., Han C., et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8:237-243.
84. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. NEngl J Med 2007, 357:228-238.
85. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
86. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
87. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001, 120:1330-1338.
88. Sandborn W.J., Feagan B.G., Radford-Smith G., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485-1493.
89. Feagan B.G., Sandborn W.J., Baker J.P., et al. Arandomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005, 21:373-384.
90. Feagan B.G., Sandborn W.J., Lichtenstein G., et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 23:617-628.
91. Schreiber S., Rutgeerts P., Fedorak R.N., et al. Arandomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
92. Feagan B.G., Sandborn W.J., Wolf D.C., et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011, 33:541-550.
93. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
94. Feagan B.G., Reinisch W., Rutgeerts P., et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007, 102:794-802.
95. Reinisch W., Sandborn W.J., Rutgeerts P., et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012, 18:201-211.
96. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
97. Gordon F.H., Hamilton M.I., Donoghue S., et al. Apilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699-705.
98. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:96-109.
99. Targan S.R., Hanauer S.B., van Deventer S.J., et al. Ashort-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. NEngl J Med 1997, 337:1029-1035.
100. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
101. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333. quiz 591.
102. Van Assche G., Vermeire S., Ballet V., et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012, 61:229-234.
103. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. NEngl J Med 2007, 357:239-250.
104. Sandborn W.J., Feagan B.G., Marano C.W., et al. 943d A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. Gastroenterology 2012, 142:S161.
105. Feagan B.G., Rutgeerts P.J., Sands B.E., et al. 943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. Gastroenterology 2012, 142:S160-S161.
106. Binion D.G., Louis E., Oldenburg B., et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol 2011, 25:492-496.
107. Feagan B.G., Bala M., Yan S., et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. JClin Gastroenterol 2005, 39:390-395.
108. Vergara M., Montserrat A., Casellas F., et al. Validation of the Spanish Work Productivity and Activity impairment questionnaire: Crohn's disease version. Eur J Gastroenterol Hepatol 2009, 21:809-815.
109. Feagan B.G., Reilly M.C., Gerlier L., et al. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010, 31:1276-1285.
110. Binion D.G., Louis E., Oldenburg B., et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol 2011, 25:492-496.
111. Vergara M., Montserrat A., Casellas F., et al. Anew validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn's disease version. Value Health 2011, 14:859-861.
112. Louis E., Lofberg R., Reinisch W., et al. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. JCrohns Colitis 2013, 7:34-43.
113. Juan J., Estiarte R., Colome E., et al. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003, 35:853-861.
114. Mesterton J., Jonsson L., Almer S.H., et al. Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis 2009, 15:1882-1890.
115. Gibson T.B., Ng E., Ozminkowski R.J., et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. JOccup Environ Med 2008, 50:1261-1272.
116. Salaffi F., Franchignoni F., Giordano A., et al. Classical test theory and Rasch analysis validation of the Recent-Onset Arthritis Disability questionnaire in rheumatoid arthritis patients. Clin Rheumatol 2013, 32:211-217.
117. Ebers G.C., Heigenhauser L., Daumer M., et al. Disability as an outcome in MS clinical trials. Neurology 2008, 71:624-631.
118. Stjernman H., Tysk C., Almer S., et al. Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease. Eur J Gastroenterol Hepatol 2011, 23:671-679.
119. Reinisch W., Sandborn W.J., Bala M., et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13:1135-1140.
120. Peyrin-Biroulet L., Cieza A., Sandborn W.J., et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis 2010, 16:15-22.
121. Peyrin-Biroulet L. What is the patient's perspective: how important are patient-reported outcomes, quality of life and disability?. Dig Dis 2010, 28:463-471.
122. Vergara M., Montserrat A., Casellas F., et al. Development and validation of the Crohn's disease perceived work disability questionnaire. Inflamm Bowel Dis 2011, 17:2350-2357.
123. Achleitner U., Coenen M., Colombel J.F., et al. Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. JCrohns Colitis 2012, 6:507-517.
124. Allen P.B., Kamm M.A., Peyrin-Biroulet L., et al. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013, 37:438-444.
125. Dur M., Sadlonova M., Haider S., et al. Health determining concepts important to people with Crohn's disease and their coverage by patient-reported outcomes of health and wellbeing. JCrohns Colitis 2014, 8:45-55.
126. van Langenberg D.R., Gibson P.R. Systematic review: fatigue in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 32:131-143.
127. Czuber-Dochan W., Ream E., Norton C. Review article: description and management of fatigue in inflammatory bowel disease. Aliment Pharmacol Ther 2013, 37:505-516.
128. Ananthakrishnan A.N., Long M.D., Martin C.F., et al. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol 2012, 11:965-971.
129. Romberg-Camps M.J., Bol Y., Dagnelie P.C., et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis 2010, 16:2137-2147.
130. Tinsley A., Macklin E.A., Korzenik J.R., et al. Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 34:1328-1336.
131. Glaus A. Fatigue in patients with cancer. Analysis and assessment. Recent Results Cancer Res 1998, 145. I-XI, 1-172.
132. Krupp L.B., LaRocca N.G., Muir-Nash J., et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123.
133. Varni J.W., Burwinkle T.M., Katz E.R., et al. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer 2002, 94:2090-2106.
134. Minderhoud I.M., Samsom M., Oldenburg B. Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?. World J Gastroenterol 2007, 13:2089-2093.
135. Zhang C.K., Hewett J., Hemming J., et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:1732-1739.
136. Graff L.A., Walker J.R., Bernstein C.N. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009, 15:1105-1118.
137. Fuller-Thomson E., Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006, 12:697-707.
138. Nahon S., Lahmek P., Durance C., et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2086-2091.
139. Ananthakrishnan A.N., Gainer V.S., Cai T., et al. Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis. Am J Gastroenterol 2013, 108:594-601.
140. Goodhand J.R., Wahed M., Mawdsley J.E., et al. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis 2012, 18:2301-2309.
141. Krugel U., Fischer J., Radicke S., et al. Antidepressant effects of TNF-alpha blockade in an animal model of depression. JPsychiatr Res 2013, 47:611-616.
142. Feagan B.G., Hanauer S.B., Coteur G., et al. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther 2011, 33:1143-1151.
143. Sands B.E., Kozarek R., Spainhour J., et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007, 13:2-11.